Sigilon Therapeutics to Present at Upcoming Scientific and Investor Conferences
CAMBRIDGE, Mass., Feb. 23, 2018 /PRNewswire/ -- Sigilon Therapeutics, a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants, today announced that the company will present at the following upcoming conferences. Presentation details are as follows:
| National Hemophilia Foundation 14th Workshop on Novel Technologies and Gene Transfer for Hemophilia |
|
| Presentation: |
Implantation of Immune Protected Cell Factories Protected by AfibromerTM Technology for the Treatment of Hemophilias |
| Presenter: |
David Peritt, Ph.D., Chief Technology Officer |
| Date: |
Saturday, Feb. 24, 2018 |
| Time: |
10:45 a.m. EST |
| Location: |
Capitol Hyatt Regency, Washington, D.C. |
| BioCentury 25th Annual Future Leaders in the Biotech Industry Conference |
|
| Presenter: |
Paul Wotton, Ph.D., Chief Executive Officer |
| Date: |
Friday, March 23, 2018 |
| Time: |
1:30 p.m. EDT |
| Location: |
Millennium Broadway Hotel & Conference Center, New York |
About Sigilon Therapeutics
Founded and created by Flagship Pioneering, Sigilon Therapeutics is a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants for the treatment of chronic diseases. Treatments based on Sigilon Therapeutics' Afibromer™ technology platform include cell implants that act as responsive "living therapeutics," providing more natural control for diseases that are currently treated with intermittent injection or infusion. Initial areas of focus include hematologic, enzyme deficiency, endocrine and metabolic disorders. More natural control would restore health and free patients from the need for therapies that are disruptive to quality of life.
For more information please visit www.sigilon.com or follow on Twitter at https://twitter.com/Sigilon_Inc.
SOURCE Sigilon Therapeutics
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article